Post-COVID Rheumatic and Immune-Mediated Diseases

A special issue of Rheumato (ISSN 2674-0621).

Deadline for manuscript submissions: closed (28 February 2023) | Viewed by 4202

Special Issue Editors


E-Mail Website
Guest Editor
Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli, 40136 Bologna, Italy
Interests: COVID; rheumatic manifestations; post-infectious autoimmune diseases; systemic sclerosis; gout; CPPD
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Medicine and Rheumatology Unit, IRCCS Istituto Ortopedico Rizzoli (IOR), Bologna, Italy
Interests: COVID; rheumatic manifestations; post-infectious autoimmune diseases; autoinflammatory diseases; connective tissue diseases

Special Issue Information

Dear Colleagues,

The potential role of viruses in the development of rheumatic diseases is well recognized, either as causative agents or as antigenic triggers for the development of autoimmunity. Inflammatory musculoskeletal manifestations following COVID-19 have been described since the earliest phases of the pandemic. Since symptoms of potential rheumatologic interest have been frequently reported in COVID-19 patients, the new virus outbreak represents a previously unseen differential diagnosis to be henceforth taken into consideration, and a “post-COVID-19 syndrome” with rheumatological manifestations is increasingly recognized as a potential complication of SARS-CoV-2 infection. Furthermore, inflammatory musculoskeletal symptoms may occasionally develop in close temporal association with COVID-19 vaccine administration. Previous studies assumed a possible association between the onset of autoimmune inflammatory diseases and vaccinations. Adjuvants may be responsible for inducing post-vaccination adverse events, in the so-called ‘ASIA’ syndrome, which represents a spectrum of presumably immune-mediated diseases secondary to the exposure to an adjuvant, associated with individual genetic predisposition.

This Special Issue aims to provide an overview of the spectrum of post-COVID-19 or post-COVID-19 vaccination rheumatic and immune-mediated diseases.

Dr. Jacopo Ciaffi
Dr. Francesco Ursini
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Rheumato is an international peer-reviewed open access quarterly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 1000 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • COVID-19
  • post-infection
  • vaccination
  • inflammatory
  • immune-mediated
  • rheumatic

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

37 pages, 1795 KiB  
Systematic Review
Non-Multisystem Inflammatory Syndrome in Children—Postacute Sequelae of Paediatric COVID-19: Autoimmune or Autoinflammatory? A Systematic Review of the Reported Cases
by Antoine Fakhry AbdelMassih, Maram Hamed Hanafy, Maryam ElAhmady, Sylvia Kozman, Nourine Diab, Reem Husseiny, Ashrakat Deyab, Aalaa Mady, Alia Yasser, Amira R. AbdelHalim, Aya Mohyeldin, Aya Sayed Serour, Ayat AbdelGadir, Eslam Abdelaziz, Farida ElGhamry, Hana Amr, Karim Milad, Lamya Fouda, Mawada Hesham, Mina Adly Riad, Mohamed Aoun, Rana AbdelTawab, Rana Sayed, Salma ElSenbawy, Sara ElAhmady Abdelkhalek, Nada Gamal and Yasmin Omaradd Show full author list remove Hide full author list
Rheumato 2023, 3(2), 132-168; https://doi.org/10.3390/rheumato3020011 - 30 May 2023
Viewed by 3216
Abstract
Three years after its emergence, coronavirus disease 2019 (COVID-19) continues to be a leading cause of worldwide morbidity and mortality. This systematic review comprises relevant case reports that discuss non-multisystem inflammatory syndrome in children (non-MIS-C) and postacute sequalae of COVID-19 (PASC) in the [...] Read more.
Three years after its emergence, coronavirus disease 2019 (COVID-19) continues to be a leading cause of worldwide morbidity and mortality. This systematic review comprises relevant case reports that discuss non-multisystem inflammatory syndrome in children (non-MIS-C) and postacute sequalae of COVID-19 (PASC) in the paediatric population, also known as long COVID syndrome. The study aims to highlight the prevalent time interval between COVID-19 and the development of non-MIS-C post-infectious sequalae (PIS). Databases were searched for studies that met our inclusion and exclusion criteria. The final screening revealed an equal sex distribution where the commonest age intervals were school-age and adolescence, with 38% of the patients being older than six years. Interestingly, hospital admission during the course of COVID-19 was not a predictor of the subsequent PASC; forty-nine patients (44.9%) were hospitalized while sixty patients (55.1%) were not hospitalized. Moreover, the most predominant time interval between COVID-19 and the developing PASC was within 14 days from the start of COVID-19 infection (61%). These findings suggest a crucial link between COVID-19 and immune PIS in the paediatric population, especially those older than six years. Accordingly, follow-up and management are encouraged in case of unusual symptoms and signs following COVID-19 infection, regardless of the COVID-19 infection severity. Full article
(This article belongs to the Special Issue Post-COVID Rheumatic and Immune-Mediated Diseases)
Show Figures

Figure 1

Back to TopTop